What the business is, and whether it's a good one at a fair price.
Sells branded pharmaceutical formulations in the Indian market through a field force of 3,100 medical representatives who visit doctors, supported by chronic and semi-chronic therapy focus that contributed 72% of FY26 revenue. The portfolio includes two brands above INR 100 crore in annual sales and eight brands in the INR 50-100 crore band; therapy mix spans women's health (ranked 5th in Gynaecology), with newer entries in biosimilars (Fostine R, Wyntide, Tyvenza) and Semaglutide for diabetes/obesity. Two acquisitions completed in FY26 — Wokadine (Povidone Iodine, #2 in that segment) for INR 20 crore and a 7-brand portfolio from Bayer Zydus — are being scaled as separate revenue lines. Manufacturing happens at an EU-GMP certified Bhayla, Ahmedabad facility, where a new women's hormone plant (194 million tablets/capsules and 1.5 million ointments/gels per year) commenced commercial production in June 2026, and the company has EAEU GMP clearance to sell into Eurasian markets. The biggest cost line is its field force and staff, with employees at 28.7% of FY26 revenue; raw materials are only 7.4% of revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from CORONA REMEDIES LIMITED's filed financials and exchange disclosures
CORONA REMEDIES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol CORONA.
Yes. Over the trailing twelve months CORONA REMEDIES LIMITED reported a net profit of ₹199 Cr on revenue of ₹1,479 Cr.
Not in the latest reported year — CORONA REMEDIES LIMITED's dividend payout for FY26 was nil.
No. Debt stands at 0.19× equity, and it carries net debt of ₹141 Cr. That is lower than 44% of its 171 Pharmaceuticals peers.
On trailing P/E, CORONA REMEDIES LIMITED ranks 144 of 169 in Pharmaceuticals — cheaper than 15% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session CORONA REMEDIES LIMITED moves 1.26% — that is the median absolute close-to-close move across its last 183 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by CORONA REMEDIES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
